HER2-positive breast cancer is a distinct subtype of breast cancer characterized by the presence of the human epidermal growth factor receptor 2 (HER2) protein. This protein contributes to the aggressive growth of cancer cells. However, targeted therapies are available to effectively treat HER2-positive breast cancer by specifically blocking the activity of HER2 protein, thereby inhibiting the growth and proliferation of cancer cells.
Targeted Therapy: Targeted therapy has revolutionized the treatment of HER2-positive breast cancer, characterized by the overexpression of the HER2 protein on cancer cells. This overexpression promotes the growth and division of cancer cells, making HER2-positive breast cancer an aggressive form of the disease.
Several targeted therapies have been developed to specifically target HER2-positive breast cancer cells and inhibit the HER2 signaling pathway. The main targeted therapies used in the treatment of HER2-positive breast cancer include:
a. Trastuzumab (Herceptin): This is a monoclonal antibody that attaches to the HER2 protein on cancer cells, preventing them from growing and dividing. Trastuzumab is often given along with chemotherapy or after surgery to reduce the risk of cancer recurrence.
b. Pertuzumab (Perjeta): Perjeta 420mg Injection is another antibody that targets HER2-positive breast cancer cells. It works in a similar way to trastuzumab but targets a different part of the HER2 protein. Pertuzumab is often given in combination with trastuzumab and chemotherapy before surgery or as maintenance therapy after surgery.
c.Small molecule inhibitors: Drugs such as lapatinib (Tykerb) and neratinib (Nerlynx) are small molecule inhibitors targeting HER2 receptors. These therapies have significantly improved outcomes and are used in various treatment settings, including adjuvant and metastatic breast cancer.
Targeted therapy provides several benefits for HER2-positive breast cancer treatment:
1.Improved survival outcomes: HER2-targeted therapies have been shown to significantly improve overall survival and disease-free survival in patients with HER2-positive breast cancer, both in the early and advanced stages of the disease.
2.Increased response rates: Targeted therapies enhance the response rates to treatment. When used in combination with chemotherapy, HER2-targeted drugs can increase the effectiveness of chemotherapy and improve tumor shrinkage.
3.Reduced recurrence risk: Targeted therapies have been shown to decrease the risk of cancer recurrence in patients with early-stage HER2-positive breast cancer, leading to long-term disease control.
It is crucial to remember that HER2-positive breast cancer is often treated holistically by combining targeted therapy with other treatment modalities such as surgery, radiation therapy, and chemotherapy. The recommended course of therapy will rely on the patient’s unique circumstances, the disease’s stage, and the advice of the medical staff.
mrmed 